Search Results - "Heal, J D"

A review of late-stage CNS drug candidates for the treatment of obesity by Heal, D J, Gosden, J, Smith, S L

“…Obesity is an important causative factor in morbidity, disability and premature death. Increasing levels of obesity will impose enormous health, financial and…”
Get full text

The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety by Heal, D.J., Cheetham, S.C., Smith, S.L.

“…Results from in vivo techniques, especially intracerebral microdialysis in freely-moving rats, have provided insights into potential mechanisms responsible for…”
Get full text

Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines by Heal, D.J., Gosden, J., Smith, S.L., Atterwill, C.K.

“…Research on classical psychedelics (psilocybin, LSD and DMT) and entactogen, MDMA, has produced a renaissance in the search for more effective drugs to treat…”
Get full text

Psychedelics: Threshold of a Therapeutic Revolution by Heal, D.J., Smith, S.L., Belouin, S.J., Henningfield, J.E.

“…This Special Issue of Neuropharmacology on psychedelics provides a timely and comprehensive update on progress following the previous Neuropharmacology Special…”
Get full text

Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine by Heal, D J, Aspley, S, Prow, M R, Jackson, H C, Martin, K F, Cheetham, S C

“…Sibutramine (BTS 54 524; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate) is a novel 5-HT (serotonin) and…”
Get more information

Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders by Heal, D J, Smith, S L, Fisas, A, Codony, X, Buschmann, H

“…The increasing global prevalence of obesity unequivocally demonstrates that neither behavioural (diet and exercise) nor pharmacological approaches to this…”
Get full text

Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence by Gray, Royston A, Heal, David J, Maguire, David R, Gerak, Lisa R, Javors, Martin A, Smith, Sharon, France, Charles P

“…Cannabidiol (CBD) is a constituent of the cannabis plant with a diverse array of pharmacological activities as well as potential therapeutic uses. An oral…”
Get full text

A comparison of the effects on central 5‐HT function of sibutramine hydrochloride and other weight‐modifying agents by Heal, D J, Cheetham, S C, Prow, M R, Martin, K F, Buckett, W R

“…1 Effects on 5‐HT function of sibutramine and its active metabolites, BTS 54 354 and BTS 54 505, were compared with fluoxetine, (+)‐fenfluramine and…”
Get full text

In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor by Gundlah, C, Martin, K F, Heal, D J, Auerbach, S B

“…Because monoamine reuptake inhibitors and releasing agents both increase extracellular neurotransmitter levels, establishing in vivo experimental criteria for…”
Get more information

Lisdexamfetamine and immediate release d-amfetamine – Differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity by Rowley, H.L., Kulkarni, R., Gosden, J., Brammer, R., Hackett, D., Heal, D.J.

“…Lisdexamfetamine mesylate (Vyvanse®) is a novel prodrug approved for attention deficit hyperactivity disorder (ADHD). It is metabolised to d-amfetamine and…”
Get full text

Thermogenic effects of sibutramine and its metabolites by Connoley, Ian P, Liu, Yong‐Ling, Frost, Ian, Reckless, Ian P, Heal, David J, Stock, Michael J

“…The thermogenic activity of the serotonin and noradrenaline reuptake inhibitor sibutramine (BTS 54524; Reductil) was investigated by measuring oxygen…”
Get full text

Modulation of sibutramine‐induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by α2‐adrenoceptors by Wortley, K E, Heal, D J, Stanford, S C

“…The effects of sibutramine (0.25–10 mg kg−1 i.p.) on extracellular noradrenaline concentration in the frontal cortex and hypothalamus of freely‐moving rats…”
Get full text

[ 3H]Nisoxetine—A radioligand for noradrenaline reuptake sites: Correlation with inhibition of [ 3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments by Cheetham, S.C., Viggers, J.A., Butler, S.A., Prow, M.R., Heal, D.J.

“…Nisoxetine is a potent and selective inhibitor of noradrenaline uptake into noradrenergic neurones. [ 3H]Nisoxetine binding to rat frontal cortical membranes…”
Get full text

Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine by Liu, Y.L, Heal, D.J, Stock, M.J

“…OBJECTIVE: To investigate the pharmacological mechanisms underlying the induction of thermogenesis by Metabolite 2 (M2; BTS 54 505), a major pharmacologically…”
Get full text

New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD by Heal, D.J., Smith, S.L., Kulkarni, R.S., Rowley, H.L.

“…Attention deficit hyperactivity disorder (ADHD) is a common childhood psychiatric condition that is effectively treated by catecholaminergic drugs with a…”
Get full text

Investigation of the mechanisms underlying the hypophagic effects of the 5‐HT and noradrenaline reuptake inhibitor, sibutramine, in the rat by Jackson, Helen C., Bearham, M. Clair, Hutchins, Lisa J., Mazurkiewicz, Sarah E., Needham, Andrew M., Heal, David J.

“…1 Sibutramine is a novel 5‐hydroxytryptamine (5‐HT) and noradrenaline reuptake inhibitor (serotonin‐ noradrenaline reuptake inhibitor, SNRI) which is currently…”
Get full text

Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine : a comparison with their abilities to evoke monoamine release by KILPATRICK, I. C, TRAUT, M, HEAL, D. J

“…It has been proposed that the anti-obesity agent, phentermine, may act in part via inhibition of monoamine oxidase (MAO). The ability of phentermine to inhibit…”
Get full text

Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat by Jackson, Helen C., Needham, Andrew M., Hutchins, Lisa J., Mazurkiewicz, Sarah E., Heal, David J.

“…1 The effects of the potent 5‐hydroxytryptamine (5‐HT) and noradrenaline reuptake inhibitor (serotonin‐noradrenaline reuptake inhibitor, SNRI), sibutramine, on…”
Get full text

Pharmacological Differences Between Rat Frontal Cortex and Hippocampus in the Nicotinic Modulation of Noradrenaline Release Implicate Distinct Receptor Subtypes by Kennett, Alexandra, Heal, David J., Wonnacott, Susan

“…Noradrenergic mechanisms in frontal cortex and hippocampus are relevant to attentional and stress-related aspects of addiction, respectively. Nicotinic…”
Get full text

[3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments by Cheetham, S C, Viggers, J A, Slater, N A, Heal, D J, Buckett, W R

“…Paroxetine is a selective and potent inhibitor of 5-hydroxytryptamine (5-HT) uptake into serotonergic neurones. [3H]Paroxetine binding to rat frontal cortex…”
Get more information